Department of Clinical Laboratory, Binzhou Medical University, Yantai, Shandong, China.
Department of Laboratory, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Int J Clin Pract. 2022 May 17;2022:4938539. doi: 10.1155/2022/4938539. eCollection 2022.
Statins are associated with gastric cancer (GC) risk. The present study aimed to clarify the efficacy of statins on the overall survival (OS) benefits in patients with GC. Publications were retrieved from PubMed, Embase, and the Cochrane Library as of April 2022. Data from the eligible cohort, case-control studies, and randomized control trials (RCTs) were extracted for the meta-analysis. Hazard ratio (HR) and 95% confidence intervals (CI) were used to assess the association between statins users and OS in GC patients. Subgroup analysis was performed based on the study design (prospective . retrospective). A total of 6 studies encompassing 5693 GC patients were included. Statins added to the standard treatment prolonged the patient's OS outcome (HR (95% CI): 0.72 (0.53-0.97), = 0.032; = 88.0%, < 0.001). A prospective study did not find any statistically significant difference in OS between statins users . nonstatin users (HR (95% CI): 0.92 (0.68-1.26), = 0.614; = 11.7%, = 0.322), whereas the retrospective studies showed prolonged OS in statins users (HR (95% CI): 0.63 (0.42-0.961), = 0.032; = 94.6%, < 0.001). Statin users had significantly improved OS compared to nonstatin users in GC treatment. This long-term survival benefit was only observed in the pooled analysis of retrospective studies but not in prospective studies.
他汀类药物与胃癌（GC）风险相关。本研究旨在阐明他汀类药物对 GC 患者总生存（OS）获益的疗效。检索了截至 2022 年 4 月 PubMed、Embase 和 Cochrane 图书馆的出版物。从合格的队列研究、病例对照研究和随机对照试验（RCT）中提取数据进行荟萃分析。使用风险比（HR）和 95%置信区间（CI）评估他汀类药物使用者与 GC 患者 OS 之间的关系。根据研究设计（前瞻性、回顾性）进行亚组分析。共纳入 6 项研究，包含 5693 例 GC 患者。与标准治疗相比，加用他汀类药物可延长患者的 OS 结局（HR（95%CI）：0.72（0.53-0.97），=0.032；=88.0%，<0.001）。前瞻性研究未发现他汀类药物使用者与非他汀类药物使用者之间 OS 存在统计学差异（HR（95%CI）：0.92（0.68-1.26），=0.614；=11.7%，=0.322），而回顾性研究则显示他汀类药物使用者 OS 延长（HR（95%CI）：0.63（0.42-0.961），=0.032；=94.6%，<0.001）。与非他汀类药物使用者相比，GC 治疗中他汀类药物使用者的 OS 明显改善。这种长期生存获益仅在回顾性研究的汇总分析中观察到，而在前瞻性研究中未观察到。
